No Data
No Data
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Express News | Amgen Shares Down 1.6% Premarket ; at Least Two Brokerages Cut PT Following Mid-Stage Data for Weight-Loss Drug
Deutsche Bank Adjusts Price Target on Amgen to $285 From $305, Maintains Hold Rating
Express News | Amgen Inc : RBC Cuts Target Price to $330 From $360
Amgen's MariTide Phase 2 Success Drives Buy Rating Amid Promising Obesity Treatment Prospects
No Data
No Data
AB84 :
Blaazin1 : His about to fix America! For whom?
章允量 :
103165865 : goog
Hero123 : mooo
View more comments...